Importance The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of
people worldwide. Tocilizumab has shown promising results in retrospective studies in …

Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …

OBJECTIVES: The results of the RECOVERY trial identified dexamethasone as the first
pharmacological therapy that reduces mortality in patients with COVID-19. The aim of this paper …

Invasive bacterial infections are a leading cause of morbidity and mortality after liver
transplant (LT), especially during the first months after LT, and infections due to multi-drug-resistant …

Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. Methods …

Objective People aging with HIV might have different health conditions compared with people
who seroconverted at older ages. The study objective was to assess the prevalence of, …

Rationale Pulse glucocorticoid therapy is used in hyperinflammation related to coronavirus
disease 2019 (COVID-19). We evaluated the efficacy and safety of pulse intravenous …

Objectives To describe our real-life experience with cefiderocol in XDR and difficult-to-treat
resistant Pseudomonas aeruginosa (DTR-P) infections without any other available treatment …

We assessed the impact of chest CT body composition parameters on outcomes and
disease severity at hospital presentation of COVID-19 patients, focusing also on the possible …

A high incidence of thrombotic events has been reported in patients with coronavirus
disease (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-…